Skip to main content
. Author manuscript; available in PMC: 2021 Jun 5.
Published in final edited form as: Circ Res. 2020 Mar 20;126(12):1779–1794. doi: 10.1161/CIRCRESAHA.120.316659

Figure 5. Fn-EDA partially contributes to myeloid cell α9-mediated stroke exacerbation.

Figure 5.

A. Schematic of experimental design. B. Left: Representative magnetic resonance imaging from 1 mouse of each group on day 1. White is the infarct area. Right: Corrected mean infarct volumes of each genotype. n=10, 10, 10, 11. C. Neurological outcome (Bederson score) from each genotype as assessed on day 1 (higher score indicates a worse outcome, n=10,10,10,11). D. The survival rate after 60 min transient ischemia. E. Modified Neurological Severity Score (mNSS) at days 1, 3, and 7 based on spontaneous activity, symmetry in the movement of 4 limbs, forepaw outstretching, climbing, body proprioception and responses to vibrissae touch (higher score indicates a better outcome). n=10, 10, 8, 9, 5, 6 and 10,11, 5, 10, 3, 6. Data are mean ± SEM (5B) and median ±range (5C, 5E). Statistical analysis: two-way ANOVA followed by Fisher’s LSD multiple comparisons test (5B), Mann-Whitney test (5C) Comparison of survival curves was evaluated by log-rank (Mantel-Cox) test (5D), Kruskal-Wallis test followed by Fisher’s LSD multiple comparisons test (5E).